Take­da to pull lung can­cer drug Exkiv­i­ty world­wide af­ter con­fir­ma­to­ry tri­al dis­ap­point­ment

Take­da is vol­un­tar­i­ly with­draw­ing its non-small cell lung can­cer drug Exkiv­i­ty from the glob­al mar­ket — start­ing with the US — months af­ter it was re­vealed the drug failed its con­fir­ma­to­ry tri­al.

On Ju­ly 27, the Japan­ese ma­jor said dur­ing its sec­ond-quar­ter earn­ings call that it had stopped the Phase III EX­CLAIM-2 tri­al for Exkiv­i­ty ear­ly due to fu­til­i­ty. The com­pa­ny re­vealed Mon­day that Exkiv­i­ty missed its pri­ma­ry end­point, and there­fore fell short of con­fir­ma­to­ry da­ta re­quired af­ter se­cur­ing ac­cel­er­at­ed ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER